Hypotrichosis
Conditions
Keywords
mild, moderate
Brief summary
The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
Interventions
DRUGtopical bimatoprost
topical bimatoprost will be applied one drop to each eyebrow each night.
Sponsors
Allergan
Kenneth Beer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Outpatient, female/male subjects of any race, 18-75 years of age. * Subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study * Patients with hypotrichosis (thinning) of the eyebrows with a GEyA score of 1 or 2. * Patient agrees to abstain from any treatment to the eyebrows including: waxing, plucking, threading, laser hair removal, and/or bleaching (excluding the glabella region). * Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. * Written informed consent and written authorization for use or release of health and research information obtained. * Willing to complete all required study visits, procedures, and evaluations including photography.
Exclusion criteria
* Subjects who are pregnant (positive urine pregnancy test), planning to become pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control. * Patients with any uncontrolled systemic disease * Patient with any known disease or abnormality of the eyebrows including eczema and seborrheic dermatitis * Patients with known or suspected trichotillomania disorder * Patients with a history of glaucoma and/or increased ocular pressure * Patients who are currently using an IOP-lowering prostaglandin analog (including Lumigan) * Patients with a known hypersensitivity to bimatoprost or any other ingredient in Latisse * Previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift, eyelid or eyebrow surgery, etc.). * Patients with permanent eye and/or eyebrow make-up * Any eyebrow tint or dye applications within 2 months prior to study entry * Any planned facial cosmetic procedure that would interfere with the evaluation of the eyebrows * Participation in another investigational drug or device study within the last 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Latisse applied to the lateral and medial eyebrow | 10 months | Increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period. |
Countries
United States
Outcome results
None listed